What is he best known for?
The fields of study he is best known for:
His primary areas of study are Biochemistry, Bacteria, Microbiology, Antibacterial agent and Antibiotics.
His work carried out in the field of Biochemistry brings together such families of science as Zinc, Moiety, Crystal structure, Molecule and Hydroxide.
His studies deal with areas such as Enzyme inhibitor and Enzyme as well as Bacteria.
His work in the fields of Enzyme, such as Biosynthesis, overlaps with other areas such as Clavulanic acid.
His studies examine the connections between Antibacterial agent and genetics, as well as such issues in Staphylococcus aureus, with regards to Reductase.
His studies in Antibiotics integrate themes in fields like Escherichia coli Proteins, Bacterial protein, Histidine kinase and Virulence.
His most cited work include:
- Drugs for bad bugs: confronting the challenges of antibacterial discovery (1778 citations)
- Alternatives to antibiotics—a pipeline portfolio review (396 citations)
- Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor. (255 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Biochemistry, Microbiology, Enzyme, Stereochemistry and Staphylococcus aureus.
His work on Antibiotics, Bacteroides fragilis and Beta-Lactamase Inhibitors is typically connected to Clavulanic acid as part of general Microbiology study, connecting several disciplines of science.
His Antibiotics study incorporates themes from Biotechnology and Intensive care medicine.
His Biotechnology research incorporates elements of Risk analysis and Antibacterial drug.
His Enzyme research includes elements of Escherichia coli, Imipenem and Bacteria.
His Stereochemistry research integrates issues from Serine, Oxidoreductase, Active site, Bacillus cereus and Enterobacter cloacae.
He most often published in these fields:
- Biochemistry (37.80%)
- Microbiology (31.71%)
- Enzyme (30.49%)
What were the highlights of his more recent work (between 2005-2018)?
- Antibiotics (17.07%)
- Biotechnology (6.10%)
- Risk analysis (3.66%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Antibiotics, Biotechnology, Risk analysis, Antibacterial drug and Computational biology.
His Antibiotics study combines topics in areas such as Histidine kinase, Escherichia coli Proteins, Bacterial protein, Bacteria and Virulence.
His study in the fields of Biotechnology industry under the domain of Biotechnology overlaps with other disciplines such as Portfolio, Phase, Modern medicine and Active engagement.
His work on Antibacterial drug is being expanded to include thematically relevant topics such as Intensive care.
His work in Computational biology is not limited to one particular discipline; it also encompasses Antibacterial activity.
His research integrates issues of High plasma and Chemical space, Drug discovery, Bioinformatics in his study of Antibiotic resistance.
Between 2005 and 2018, his most popular works were:
- Drugs for bad bugs: confronting the challenges of antibacterial discovery (1778 citations)
- Alternatives to antibiotics—a pipeline portfolio review (396 citations)
- Desperately Seeking New Antibiotics (143 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
